SCHEMBL24008483

SCHEMBL24008483

O[C@H]1[C@H](O)CN(CC2CCCCC2)C[C@@H]1O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GBA1 P04062 6/20 0.70
▸ CHRM5 P08912 2/20 0.52
▸ ADRA2C P18825 1/20 0.52
▸ ACHE P22303 1/20 0.45
▸ CHRM2 P08172 1/20 0.41
▸ CHRM4 P08173 1/20 0.41
▸ CHRM1 P11229 1/20 0.41
▸ GLB1 P16278 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ SCN1A P35498 1/20 0.39
▸ SCN4A P35499 1/20 0.39
▸ SCN7A Q01118 1/20 0.39
▸ KCNH2 Q12809 1/20 0.39
▸ SCN5A Q14524 1/20 0.39
▸ SCN9A Q15858 1/20 0.39
▸ SCN2A Q99250 1/20 0.39
▸ SCN3A Q9NY46 1/20 0.39
▸ SCN11A Q9UI33 1/20 0.39
▸ SCN8A Q9UQD0 1/20 0.39
▸ SCN10A Q9Y5Y9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30322982 1.00 GBA1 (0.70) GBA1CHRM5ADRA2CACHECHRM2
SCHEMBL2717184 0.85 GBA1 (0.97) GBA1CHRM5ADRA2C
SCHEMBL24256245 0.84 GBA1 (0.60) GBA1CHRM5ADRA2CACHECHRM2
SCHEMBL2716774 0.83 GBA1 (1.00) GBA1
SCHEMBL26633151 0.83 GBA1 (0.55) GBA1CHRM5ADRA2CGLB1SCN1A
SCHEMBL26633180 0.83 GBA1 (0.55) GBA1CHRM5ADRA2CGLB1SCN1A
SCHEMBL26633178 0.83 GBA1 (0.55) GBA1CHRM5ADRA2CGLB1SCN1A
SCHEMBL24008488 0.79 GBA1 (0.51) GBA1GLB1SCN1ASCN4ASCN7A
SCHEMBL24008737 0.79 GBA1 (0.47) GBA1GLB1SIGMAR1UGCGGBA2
SCHEMBL30323091 0.79 GBA1 (0.47) GBA1GLB1SIGMAR1UGCGGBA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348387-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC. (CA) 2023-11-02 — — US disclosed
US-20230348387-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC. (CA) 2023-11-02 — — US disclosed
WO-2021224864-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC. (CA) 2021-11-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348387-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF GBA1, GBA2, GAA GBA1 1/4885CHRM5 4735/4885ADRA2C 4295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback